EDGAR·FLOW

Korsana Biosciences, Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 88/100
What the filing says
Korsana completed a merger with Cyclerion Therapeutics in September 2026 concurrent with a $380 million private placement, resulting in cash and equivalents of $456.2 million as of Q3 2026—sufficient to fund operations into 2029. The company strengthened leadership (new CMO, CTO, audit chair) and advanced lead program KRSA-028 with Phase 1 healthy volunteer data expected mid-2027 and proof-of-concept data in Alzheimer's patients by year-end 2027 or Q1 2028. Q3 R&D expenses were $42.1 million; net loss was $46.4 million on 55.1 million shares outstanding.
Why this rating

Merger adds $456M cash (80× company market cap) and transformational resources for pre-clinical biotech. Enables 2.5+ year runway and near-term clinical catalysts.

Tradability signal
NO TRADE

No trade: positive news with only -0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=325). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$30.30
+10 min · unknown
$30.29 ▼ 0.03%
+30 min · unknown
$30.12 ▼ 0.59%
+1 hr · unknown
$29.91 ▼ 1.30%
+4 hrs · unknown
$30.13 ▼ 0.58%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ KRSA · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.